GlassScriptPhysician profile
Jeffrey S Kim
NPI 1073648994
$8,998.08
in general payments reported to CMS, 2019-2025
36 companies · $2,104 in 2025
The $2,104 reported for 2025 was more than what 77% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,362 · 2020: $242 · 2021: $684 · 2022: $1,418 · 2023: $1,648 · 2024: $1,539 · 2025: $2,104.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,050 · Education: $241.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,050.42 |
| Education | $240.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,548.38 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals LP | $1,407.90 | 2019-2025 | Fasenra, Tezspire, Airsupra |
| Insmed, INC. | $753.86 | 2019-2025 | Arikayce, Brinsupri |
| Philips North America LLC | $570.24 | 2019-2025 | Vest Therapy Und, (Ak6) Vest Therapy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $521.13 | 2019-2024 | Ofev, Spiriva Respimat |
| Genzyme Corporation | $438.59 | 2021-2025 | |
| Grifols USA, LLC | $436.00 | 2019-2025 | Xembify, Prolastin-C Liquid |
| Mylan Specialty L.P. | $396.38 | 2019-2024 | Yupelri |
| Electromed, INC. | $263.29 | 2019-2025 | Smartvest |
| Regeneron Healthcare Solutions, INC. | $258.93 | 2021-2025 | Dupixent |
| Harmony Biosciences LLC | $219.43 | 2023-2025 | Wakix |
| Sunovion Pharmaceuticals INC. | $209.21 | 2019 | |
| Baxter Healthcare | $197.05 | 2022-2025 | Hillrom - Life 2000 Ventilation System, Hillrom - Vest System Model 105 Home Care, Hillrom - Monarch Airway Clearance System |
| Actelion Pharmaceuticals US, INC. | $180.34 | 2023-2025 | Opsumit |
| Sanofi-Aventis U.S. LLC | $172.98 | 2024-2025 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| United Therapeutics Corporation | $170.51 | 2022-2025 | Tyvaso, Tyvaso, Orenitram |
| Viatris Specialty LLC | $154.68 | 2025 | Yupelri |
| Amgen INC. | $116.44 | 2023-2025 | Tezspire, Tavneos |
| Takeda Pharmaceuticals U.S.A., INC. | $110.55 | 2022-2025 | Glassia, Aralast |
| Covis Pharma Gmbh | $104.54 | 2021-2023 | |
| Verona Pharma, INC. | $80.61 | 2025 | Ohtuvayre |
| Jazz Pharmaceuticals INC. | $71.92 | 2019-2025 | |
| Circassia INC. | $71.26 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $65.46 | 2019-2023 | |
| Idorsia Pharmaceuticals US INC | $57.37 | 2022-2023 | Quviviq |
| Mallinckrodt Enterprises LLC | $56.84 | 2019 | |
| Pfizer INC. | $55.78 | 2022-2023 | |
| Lilly USA, LLC | $53.64 | 2025 | Zepbound |
| Teva Pharmaceuticals USA, INC. | $53.42 | 2019-2022 | |
| Azurity Pharmaceuticals, INC. | $50.51 | 2023-2025 | Horizant, Horizant |
| Optinose US, INC. | $46.18 | 2024-2025 | |
| Inspire Medical Systems, INC. | $36.10 | 2023-2024 | Inspire |
| Avadel Cns Pharmaceuticals, LLC | $18.69 | 2025 | Lumryz |
| Inogen, INC. | $18.33 | 2025 | |
| Tactile Systems Technology INC | $18.06 | 2021 | |
| Resmed Corp | $13.48 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Kim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.